By selecting patients with adenocarcinoma who had never smoked, the administration of gefitinib in patients with advanced or metastatic NSCLC had a marked OR of ~55.6% (14), which was comparable to gefitinib for EGFR mutation-positive patients with PS 0–2 (15–20). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.